Literature DB >> 25057450

Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma.

Derek A Wainwright1, Maciej S Lesniak1.   

Abstract

Glioblastoma is an aggressive primary brain cancer. Given our interest in novel immunotherapies, we have recently shown that inhibiting CTLA-4, PD-L1 and IDO results in a dramatic survival advantage in mice with brain tumors. Our preclinical study supports the rapid translation of this approach into phase I clinical trial.

Entities:  

Keywords:  glioblastoma; immunosuppression; immunotherapy; metabolism; tryptophan

Year:  2014        PMID： 25057450      PMCID： PMC4091585          DOI： 10.4161/onci.28927

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme.

Authors:  Abdeljabar El Andaloussi; Maciej S Lesniak
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

2.  Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism.

Authors:  Vladimir V Didenko; Hop N Ngo; Candace Minchew; David S Baskin
Journal:  J Neurosurg       Date:  2002-03       Impact factor: 5.115

3.  Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors.

Authors:  Abdeljabar El Andaloussi; Yu Han; Maciej S Lesniak
Journal:  J Neurosurg       Date:  2006-09       Impact factor: 5.115

4.  Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.

Authors:  Peter E Fecci; Alison E Sweeney; Peter M Grossi; Smita K Nair; Christopher A Learn; Duane A Mitchell; Xiuyu Cui; Thomas J Cummings; Darell D Bigner; Eli Gilboa; John H Sampson
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

5.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

6.  Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

Authors:  Jedd D Wolchok; James P Allison; Dmitriy Zamarin; Rikke B Holmgaard; Sumit K Subudhi; Joon Seok Park; Mena Mansour; Peter Palese; Taha Merghoub
Journal:  Sci Transl Med       Date:  2014-03-05       Impact factor: 17.956

7.  Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells.

Authors:  Eric D Mortenson; SaeGwang Park; Zhujun Jiang; Shengdian Wang; Yang-Xin Fu
Journal:  Clin Cancer Res       Date:  2013-01-30       Impact factor: 12.531

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.

Authors:  Derek A Wainwright; Alan L Chang; Mahua Dey; Irina V Balyasnikova; Chung Kwon Kim; Alex Tobias; Yu Cheng; Julius W Kim; Jian Qiao; Lingjiao Zhang; Yu Han; Maciej S Lesniak
Journal:  Clin Cancer Res       Date:  2014-04-01       Impact factor: 12.531
  9 in total
  4 in total

Review 1.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 2.  Novel immunotherapies for hematologic malignancies.

Authors:  Michelle H Nelson; Chrystal M Paulos
Journal:  Immunol Rev       Date:  2015-01       Impact factor: 12.988

3.  Is an Immunosuppressive Microenvironment a Characteristic of Both Intra- and Extraparenchymal Central Nervous Tumors?

Authors:  Amina Soltani; Bela Kajtar; El Husseiny Mohamed Mahmud Abdelwahab; Anita Steib; Zsolt Horvath; Laszlo Mangel; Luca Jaromi; Judit E Pongracz
Journal:  Pathophysiology       Date:  2021-01-08

4.  Irradiation-Modulated Murine Brain Microenvironment Enhances GL261-Tumor Growth and Inhibits Anti-PD-L1 Immunotherapy.

Authors:  Joel R Garbow; Tanner M Johanns; Xia Ge; John A Engelbach; Liya Yuan; Sonika Dahiya; Christina I Tsien; Feng Gao; Keith M Rich; Joseph J H Ackerman
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.